LENIOBIO GMBH
Budget
€1 — €0
EP Access
0
accredited persons
Staff
3
0.3 FTE
EU Grants
None
Mission & Goals
LenioBio GmbH develops scalable eukaryotic cell-free protein expression technologies enabling rapid and flexible production of complex proteins. Its proprietary platform facilitates expression of membrane proteins, antibodies, virus-like particles, and proteins with complex post-translational modifications, supporting applications from research to biomanufacturing and vaccine development. The technology addresses key bottlenecks in traditional protein production, offering fast turnaround, batch consistency, and the potential for integration with rapid DNA template synthesis. LenioBio collaborates with leading industry partners and continually advances its platform for broad accessibility and application in life sciences.
EU Legislative Interests
Interest in joining the HERA Joint Industrial Cooperation Forum
Communication Activities
LenioBio is the grantee of an EU4Health grant (GA 101203358) since 01/07/2025, running through until 31/12/2027. The Press Release relating to this grant can be found on LenioBio's website at: https://www.leniobio.com/press-release/leniobio-secures-eur-3-7m-of-eu4health-funding-to-develop-alice-for-cost-effective-and-rapid-production-of-protein-based-medicines/. The grant comes as part of the first wave of HERA Action Grants and a significant Work Package within this project is related to Dissemination & Communication, where LenioBio will present on the project results and aims, and how they contribute to HERA objectives (for example at the recent World Vaccine Congress Europe, Amsterdam, October 2025 (13/10/2025-16/10/2025). Additionally, since 01/11/2025 LenioBio is a beneficiary within the EDF-2024-RA-SGA (101201953) and EDF-2024-DA-SGA (101201939) projects. These projects are part of the RESILIENCE Framework Partnership Agreement, arranged to prioritise funding for medical countermeasures research and development by the European Defence Fund. Considering the sensitive nature of these project, communication activities are limited but will synergise with the EU4Health project considering the similar themes.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Biotechnology Innovation Organisation Association (https://www.bio.org/) RESILIENCE FPA (https://defence-industry-space.ec.europa.eu/document/download/44b52bbc-353a-4b29-bac7-3ffa3e9489fc_en?filename=RESILIENCE%20-%20Factsheet_EDF22.pdf) Biodeutschland association for independent (https://www.biodeutschland.org/en/association.html) American association of chemical engineering (https://www.aiche.org/) Medical Technology Enterprise Consortium (https://mtec-sc.org/)
Additional Information
This estimate of annual costs is informed by the EU4H-2024-PJ-01-3 project, pre-financed with €696,000 in 2025. The project is reimbursed at a 60% and so the real annual costs of LenioBio are estimated to be €1,160,000. Additionally, the EDF-2024-RA-SGA and EDF-2024-DA-SGA programmes have been added.
Connected Legislation
Commissioner Meetings
No recorded meetings with EU commissioners.